2026-04-26T23:12:46Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/259582025-12-18T12:56:19Zcom_20.500.12105_2327com_20.500.12105_2290col_20.500.12105_16991

00925njm 22002777a 4500 dc García-Silva, Susana author Benito-Martín, Alberto author Sánchez-Redondo, Sara author Hernández-Barranco, Alberto author Ximénez-Embún, Pilar author Nogués, Laura author Mazariegos, Marina S author Brinkmann, Kay author Amor López, Ana author Meyer, Lisa author Rodríguez, Carlos author García-Martín, Carmen author Boskovic, Jasminka author Letón, Rocío author Montero, Cristina author Robledo Batanero, Mercedes author Santambrogio, Laura author Sue Brady, Mary author Szumera-Ciećkiewicz, Anna author Kalinowska, Iwona author Skog, Johan author Noerholm, Mikkel author Muñoz, Javier author Ortiz-Romero, Pablo L author Ruano, Yolanda author Rodríguez-Peralto, José L author Rutkowski, Piotr author Peinado Selgas, Hector author 2019-05-06 Liquid biopsies from cancer patients have the potential to improve diagnosis and prognosis. The assessment of surrogate markers of tumor progression in circulating extracellular vesicles could be a powerful non-invasive approach in this setting. We have characterized extracellular vesicles purified from the lymphatic drainage also known as exudative seroma (ES) of stage III melanoma patients obtained after lymphadenectomy. Proteomic analysis showed that seroma-derived exosomes are enriched in proteins resembling melanoma progression. In addition, we found that the mutation can be detected in ES-derived extracellular vesicles and its detection correlated with patients at risk of relapse. J Exp Med . 2019 May 6;216(5):1061-1070. https://hdl.handle.net/20.500.12105/25958 30975894 Journal of Experimental Medicine MUTANT KRAS EXOXOME DNA CELLS Use of extracellular vesicles from lymphatic drainage as surrogate markers of melanoma progression and mutation.